A Plus Biotechnology Co Ltd

As of June 30, 2026, A Plus Biotechnology Co Ltd carries a market capitalization of 2.46B, placing it among publicly traded companies globally. Its enterprise value stands at 2.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, A Plus Biotechnology Co Ltd has 34.07M shares outstanding.

As of June 30, 2026, A Plus Biotechnology Co Ltd trades at a trailing price-to-earnings ratio of 13.31. The price-to-sales ratio is 2.79, and the price-to-book ratio stands at 2.05.

As of June 30, 2026, A Plus Biotechnology Co Ltd trades at an EV/EBITDA multiple of 8.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.10 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. A Plus Biotechnology Co Ltd trades at an EV/FCF ratio of 63.33, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.15B versus a market cap of 2.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, A Plus Biotechnology Co Ltd maintains a current ratio of 5.83, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.02, indicating elevated leverage, while an interest coverage ratio of 97.16 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, A Plus Biotechnology Co Ltd posted a return on equity (ROE) of 15.48, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.45 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.36, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.01, useful for judging operating efficiency across full business cycles. The company generates approximately 5.43M in revenue per employee across its workforce of 163.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.88 indicates how many times A Plus Biotechnology Co Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, A Plus Biotechnology Co Ltd recorded 48.34M in income tax expense. That works out to an effective tax rate of 20.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 234.58M, leaving 185.79M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, A Plus Biotechnology Co Ltd's stock has declined approximately 15.90% over the past 52 weeks. The 50-day moving average sits at 74.92, while the 200-day moving average is 77.08.

Over the twelve months ended June 30, 2026, A Plus Biotechnology Co Ltd generated 887.93M in revenue and converted that into 185.79M in net income, yielding earnings per share of 5.43. EBITDA reached 242.42M, while operating income came in at 213.27M.

As of June 30, 2026, A Plus Biotechnology Co Ltd holds 481.56M in cash and equivalents against 168.69M in total debt, resulting in a net debt position of -311.43M. Total book value stands at 1.20B, with working capital of 884.65M providing operational flexibility.

A Plus Biotechnology Co Ltd produced 169.55M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -137.52M in capital expenditures, free cash flow totaled 32.03M - equivalent to 0.94 per share.

Over the twelve months ended June 30, 2026, A Plus Biotechnology Co Ltd posted a gross margin of 66.77, reflecting its pricing power and cost economics. The operating margin of 24.02 and net profit margin of 20.92 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, A Plus Biotechnology Co Ltd paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.29, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to A Plus Biotechnology Co Ltd shareholders.

As of June 30, 2026, A Plus Biotechnology Co Ltd has an Altman Z-Score of 6.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.